Revance Therapeutics, Inc. Contracts & Agreements

Amendment to the Amended and Restated Agreement and Plan of Merger, by and among Crown Laboratories, Inc., Reba Merger Sub, Inc. and Revance Therapeutics, Inc. dated as of... (Filed With SEC on December 12, 2024)

Amended and Restated Agreement and Plan of Merger, by and among Crown Laboratories, Inc., Reba Merger Sub, Inc. and Revance Therapeutics, Inc. dated as of December 7, 2024 (Filed With SEC on December 9, 2024)

Amended and Restated Support Agreement, dated as of December 7, 2024, by and among Crown Laboratories, Inc., Reba Merger Sub, Inc. and the parties named on Schedule A thereto... (Filed With SEC on December 9, 2024)

Fourth Amendment to Exclusive Distribution Agreement dated June 13, 2024 by and between Revance Therapeutics, Inc. and Teoxane SA (Filed With SEC on November 7, 2024)

Fifth Amendment to Exclusive Distribution Agreement dated July 29, 2024 by and between Revance Therapeutics, Inc. and Teoxane SA (Filed With SEC on November 7, 2024)

Sixth Amendment to the Exclusive Distribution Agreement, dated October 24, 2024, by and among Teoxane SA and Revance Therapeutics, Inc (Filed With SEC on October 28, 2024)

Exclusive Distribution Agreement, dated October 24, 2024, by and among Teoxane SA, Revance Therapeutics, Inc. and Revance Australia Pty. Ltd (Filed With SEC on October 28, 2024)

Agreement and Plan of Merger, by and among Crown Laboratories, Inc., Reba Merger Sub, Inc. and Revance Therapeutics, Inc. dated as of August 11, 2024 (Filed With SEC on August 12, 2024)

Offer Letter dated September 29, 2022 by and between Revance Therapeutics, Inc. and David Hollander, MD (Filed With SEC on May 9, 2024)

Offer Letter dated February 21, 2023 by and between Revance Therapeutics, Inc. and Erica Jordan (Filed With SEC on May 9, 2024)

Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on May 9, 2024)

Underwriting Agreement, dated March 4, 2024, by and between the Company and the Underwriter (Filed With SEC on March 5, 2024)

Description of Registrants Securities (Filed With SEC on February 28, 2024)

Revance Therapeutics, Inc. 202 (Filed With SEC on February 28, 2024)

Amendment No. 2 to the Technology Transfer, Validation and Commercial Fill/Finish Services Agreement dated February 26, 2024, by and between Revance Therapeutics, Inc. and... (Filed With SEC on February 28, 2024)

Separation Agreement dated February 23, 2024 by and between Revance Therapeutics, Inc. and Dustin Sjuts (Filed With SEC on February 28, 2024)

Amended and Restated Executive Severance Benefit Plan (Filed With SEC on February 13, 2024)

License and Service Agreement dated February 8, 2007, by and between Revance Therapeutics, Inc. and List Biological Laboratories, Inc (Filed With SEC on May 9, 2023)

First Addendum to the License and Service Agreement dated April 21, 2009, by and between Revance Therapeutics, Inc. and List Biological Laboratories, Inc (Filed With SEC on May 9, 2023)

Third Amendment to Lease dated January 13, 2023, by and between Revance Therapeutics, Inc. and 1222 Demonbreun, LP (Filed With SEC on May 9, 2023)

Second Letter Amendment to License Agreement dated (Filed With SEC on May 9, 2023)

Description of Registrants Securities (Filed With SEC on February 28, 2023)

Form of Restricted Stock Unit Agreement and Grant Notice under Amended and Restated Revance Therapeutics, Inc. 2014 Inducement Plan (Filed With SEC on February 28, 2023)

Revance Therapeutics, Inc. 202 (Filed With SEC on February 28, 2023)

Third Amendment to Exclusive Distribution Agreement dated December 22, 2022, by and between Revance Therapeutics, Inc. and Teoxane SA (Filed With SEC on February 28, 2023)

Second Amendment to Exclusive Distribution Agreement, dated November 18, 2020, by and between Revance Therapeutics, Inc. and Teoxane SA (Filed With SEC on November 8, 2022)

Underwriting Agreement, dated September 12, 2022, by and among the Company and the Underwriters (Filed With SEC on September 14, 2022)

Separation Agreement dated February 25, 2022 by and between Revance Therapeutics, Inc. and Abhay Joshi (Filed With SEC on May 10, 2022)

Third Addendum to License and Service Agreement dated December 9, 2021 between Revance Therapeutics, Inc. and List E, LLC (Filed With SEC on May 10, 2022)

Note Purchase Agreement dated March 18, 2022 among Revance Therapeutics, Inc., certain subsidiaries of Revance Therapeutics, Inc., Athyrium Buffalo LP and the purchasers from time... (Filed With SEC on May 10, 2022)

Description of Registrants Securities (Filed With SEC on February 28, 2022)

Revance Therapeutics, Inc. 2022 Management Bonus Plan (Filed With SEC on February 28, 2022)

Technology Transfer, Validation and Commercial Fill/Finish Services Agreement dated March 14, 2017 between Revance Therapeutics, Inc. and Ajinomoto Althea, Inc (Filed With SEC on February 28, 2022)

Separation Agreement (Filed With SEC on February 28, 2022)

Second Amendment to Lease, dated July 1, 2021 by and between Revance Therapeutics, Inc and 1222 Demonbreun, LP (Filed With SEC on November 9, 2021)

Commercial Supply Agreement, effective as of April 6, 2021, by and between Revance Therapeutics, Inc. and Lyophilization Services of New England, Inc (Filed With SEC on August 5, 2021)

Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on May 10, 2021)

Second Addendum to License and Service Agreement, dated March 2, 2021 between Revance Therapeutics, Inc. and List Biological Laboratories, Inc (Filed With SEC on May 10, 2021)

Description of Registrants Securities (Filed With SEC on February 25, 2021)

Form of Restricted Stock Bonus Agreement and Grant Notice for Revance Therapeutics, Inc. 2014 Equity Incentive Plan (Filed With SEC on February 25, 2021)

Form of Restricted Stock Agreement and Grant Notice under Amended and Restated Revance Therapeutics, Inc. 2014 Inducement Plan (Filed With SEC on February 25, 2021)

Amendment to Lease, effective as of January 4, 2021, by and between Revance Therapeutics, Inc. and 1222 Demonbreun, LP (Filed With SEC on February 25, 2021)

Revance Therapeutics, Inc. 2021 Management Bonus Plan (Filed With SEC on February 25, 2021)

Amendment No. 1 to the Technology Transfer, Validation and Commercial Fill/Finish Services Agreement dated December 18, 2020 between Revance Therapeutics, Inc. and Ajinomoto... (Filed With SEC on February 25, 2021)

Letter Amendment to the License Agreement dated January 8, 2020 by and between Revance Therapeutics, Inc. and Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd (Filed With SEC on February 25, 2021)

Office Lease Agreement dated November 19, 2020 (Filed With SEC on November 20, 2020)

Executive Employment Agreement effective July 23, 2020 by and between Revance Therapeutics, Inc. and Aubrey Rankin (Filed With SEC on November 9, 2020)

Revance Therapeutics, Inc. Amended and Restated 2014 Inducement Plan (Filed With SEC on November 9, 2020)

First Amendment to Exclusive Distribution Agreement (Filed With SEC on November 9, 2020)

Fifth Amendment to Lease, dated July 1, 2020, by and between Revance Therapeutics, Inc. and BMR-Pacific Research Center LP (Filed With SEC on August 6, 2020)

Form of Voting Agreement by and between Revance Therapeutics, Inc. and each of the parties named in each agreement therein (Filed With SEC on June 10, 2020)

Form of Lock-Up Agreement by and between Revance Therapeutics, Inc. and each of the parties named in each agreement therein (Filed With SEC on June 10, 2020)

Loan Agreement, dated May 18, 2020, by and between Revance Therapeutics, Inc. and Hint, Inc (Filed With SEC on June 10, 2020)

Description of Registrants Securities (Filed With SEC on February 26, 2020)

Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 26, 2020)

Revance Therapeutics, Inc. 2020 Management Bonus Plan (Filed With SEC on February 26, 2020)

Executive Employment Agreement effective December 1, 2019 and between Revance Therapeutics, Inc. and Dustin Sjuts (Filed With SEC on February 26, 2020)

Separation Agreement effective January 8, 2020 by and between Revance Therapeutics, Inc. and Caryn G. McDowell (Filed With SEC on February 26, 2020)

Executive Employment Agreement dated February 17, 2020 by and between Revance Therapeutics, Inc. and Dwight Moxie (Filed With SEC on February 26, 2020)

Exclusive Distribution Agreement, dated January 10, 2020, by and between Revance Therapeutics, Inc. and Teoxane SA (Filed With SEC on February 26, 2020)

Indenture, dated as of February 14, 2020, by and between Revance Therapeutics, Inc. and U.S. Bank National Association, as Trustee (Filed With SEC on February 14, 2020)

Underwriting Agreement, dated December 4, 2019, by and among the Company and the Underwriters (Filed With SEC on December 4, 2019)

Amendment #1 to the Collaboration and License Agreement dated August 22, 2019 between Revance Therapeutics, Inc. and Mylan Ireland Ltd (Filed With SEC on November 4, 2019)

Separation Agreement effective October 11, 2019 by and between Revance Therapeutics, Inc. and L. Daniel Browne (Filed With SEC on November 4, 2019)

Revance Therapeutics, Inc. Executive Severance Benefit Plan, Amended and Restated effective October 13, 2019 (Filed With SEC on November 4, 2019)

Executive Employment Agreement effective October 13, 2019 by and between Revance Therapeutics, Inc. and Mark J. Foley (Filed With SEC on November 4, 2019)

Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on November 4, 2019)

Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on May 9, 2019)

Revance Therapeutics, Inc. Executive Severance Benefit Plan, Amended and Restated Effective February 12, 2019 (Filed With SEC on May 9, 2019)

Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 28, 2019)

Revance Therapeutics, Inc. 2019 Management Bonus Plan (Filed With SEC on February 28, 2019)

Executive Employment Agreement dated November 5, 2018 by and between Revance Therapeutics, Inc. and Tobin Schilke (Filed With SEC on February 28, 2019)

Employment Agreement dated November 7, 2018 by and between Revance Therapeutics, Inc. and Cyril Allouche (Filed With SEC on February 28, 2019)

License Agreement, dated December 4, 2018, by and between Revance Therapeutics, Inc. and Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd (Filed With SEC on February 28, 2019)

Underwriting Agreement, dated January 16, 2019, by and among the Company and the Underwriters (Filed With SEC on January 17, 2019)

Executive Employment Agreement dated May 1, 2018 by and between Company and Caryn G. McDowell (Filed With SEC on August 3, 2018)

First Amendment to Manufacture and Development Agreement dated April 13, 2018 between the Company and Bachem Americas, Inc (Filed With SEC on August 3, 2018)

Fourth Amendment to Lease, dated May 10, 2018, by and between the Company and BMR-Pacific Research Center LP (Filed With SEC on May 11, 2018)

Collaboration and License Agreement by and between the Company and Mylan Ireland Ltd, dated as of February 28, 2018 (Filed With SEC on May 9, 2018)

Revance Therapeutics, Inc. Third Amended and Restated Executive Severance Benefit Plan (Filed With SEC on March 2, 2018)

Revance Therapeutics, Inc. 2018 Management Bonus Plan (Filed With SEC on March 2, 2018)

Underwriting Agreement, dated December 6, 2017, by and among the Company, the Selling Stockholders and the Underwriters (Filed With SEC on December 7, 2017)

Executive Employment Agreement by and between the Company and Todd Zavodnick, dated as of September 18, 2017 (Filed With SEC on November 3, 2017)

Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on May 9, 2017)

Technology Transfer, Validation and Commercial Fill/Finish Services Agreement (Filed With SEC on May 9, 2017)

REVANCE THERAPEUTICS, INC. Second Amended and Restated EXECUTIVE SEVERANCE BENEFIT PLAN (Filed With SEC on February 28, 2017)

REVANCE THERAPEUTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on February 28, 2017)

REVANCE THERAPEUTICS, INC. 2017 MANAGEMENT BONUS PROGRAM (Filed With SEC on February 28, 2017)

REVANCE THERAPEUTICS, INC. $75,000,000 COMMONSTOCK SALES AGREEMENT (Filed With SEC on March 7, 2016)

REVANCE THERAPEUTICS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2014 EQUITY INCENTIVE PLAN) (Filed With SEC on March 4, 2016)

REVANCE THERAPEUTICS, INC. RESTRICTED STOCK BONUS GRANT NOTICE (2014 EQUITY INCENTIVE PLAN) (Filed With SEC on March 4, 2016)

REVANCE THERAPEUTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on March 4, 2016)

REVANCE THERAPEUTICS, INC. 2016 MANAGEMENT BONUS PROGRAM (Filed With SEC on March 4, 2016)

REVANCE THERAPEUTICS, INC. 2014 INDUCEMENT PLAN RESTRICTED STOCK GRANT NOTICE (Filed With SEC on March 4, 2016)

EXECUTIVE EMPLOYMENT AGREEMENT for Abhay Joshi, PhD, MBA (Filed With SEC on March 4, 2016)

SECOND AMENDMENT to DEVELOPMENT AND SUPPLY AGREEMENT between REVANCE THERAPEUTICS, INC. and HOSPIRA WORLDWIDE, INC. (Filed With SEC on November 10, 2015)

REVANCE THERAPEUTICS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2014 EQUITY INCENTIVE PLAN) (Filed With SEC on November 10, 2015)

REVANCE THERAPEUTICS, INC. STOCK OPTION GRANT NOTICE (2014 EQUITY INCENTIVE PLAN) (Filed With SEC on November 10, 2015)

REVANCE THERAPEUTICS, INC. RESTRICTED STOCK BONUS GRANT NOTICE (2014 EQUITY INCENTIVE PLAN) (Filed With SEC on November 10, 2015)

REVANCE THERAPEUTICS, INC. 2014 INDUCEMENT PLAN STOCK OPTION GRANT NOTICE (Filed With SEC on November 10, 2015)

REVANCE THERAPEUTICS, INC. 2014 INDUCEMENT PLAN RESTRICTED STOCK GRANT NOTICE (Filed With SEC on November 10, 2015)

3,250,000 Shares Revance Therapeutics, Inc. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on November 4, 2015)

Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on August 7, 2015)

Appendix A (Filed With SEC on May 14, 2015)

FIRST AMENDMENT TO DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENT ___________________________________ (Filed With SEC on May 14, 2015)

REVANCE THERAPEUTICS, INC. AMENDED AND RESTATED EXECUTIVE SEVERANCE BENEFIT PLAN (Filed With SEC on May 13, 2015)

SECOND AMENDMENT TO LOAN AND LEASE AGREEMENT (Filed With SEC on March 4, 2015)

REVANCE THERAPEUTICS, INC. WARRANT TO PURCHASE CAPITAL STOCK (Filed With SEC on March 4, 2015)

REVANCE THERAPEUTICS, INC. $50,000,000 COMMON STOCK SALES AGREEMENT (Filed With SEC on March 4, 2015)

FIRST AMENDMENT TO LOAN ANDLEASE AGREEMENT (Filed With SEC on December 22, 2014)

REVANCE THERAPEUTICS, INC. 2014 INDUCEMENT PLAN ADOPTED BY BOARD ON: AUGUST 29, 2014 AS AMENDED ON: SEPTEMBER 17, 2014 TERMINATION DATE: AUGUST 29, 2024 (Filed With SEC on November 13, 2014)

EXECUTIVE EMPLOYMENT AGREEMENT for Arthur P. Bertolino,MD, PhD, MBA (Filed With SEC on November 13, 2014)

REVANCE THERAPEUTICS, INC. 2014 INDUCEMENT PLAN ADOPTED BY BOARD ON: AUGUST 26, 2014 TERMINATION DATE: AUGUST 26, 2024 (Filed With SEC on August 29, 2014)

REVANCE THERAPEUTICS, INC. 2014 INDUCEMENT PLAN STOCK OPTION GRANT NOTICE (Filed With SEC on August 29, 2014)

REVANCE THERAPEUTICS, INC. 2014 INDUCEMENT PLAN RESTRICTED STOCK GRANT NOTICE (Filed With SEC on August 29, 2014)

[] Shares Revance Therapeutics, Inc. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on June 16, 2014)

Appendix A (Filed With SEC on June 16, 2014)

REVANCE THERAPEUTICS, INC. 2014 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (Filed With SEC on May 14, 2014)

REVANCE THERAPEUTICS, INC. 2014 MANAGEMENT BONUS PROGRAM (Filed With SEC on March 28, 2014)

THIRD AMENDMENT TO LEASE (Filed With SEC on March 4, 2014)

[] Shares Revance Therapeutics, Inc. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on January 27, 2014)

REVANCE THERAPEUTICS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (Filed With SEC on January 27, 2014)

REVANCE THERAPEUTICS, INC. 2014 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:JANUARY 22, 2014 APPROVED BY THE STOCKHOLDERS:JANUARY 23, 2014 IPO DATE/EFFECTIVE DATE:[ ],... (Filed With SEC on January 27, 2014)

REVANCE THERAPEUTICS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2014 EQUITY INCENTIVE PLAN) (Filed With SEC on January 27, 2014)

REVANCE THERAPEUTICS, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS:JANUARY 22, 2014 APPROVED BY THE STOCKHOLDERS:JANUARY 23, 2014 (Filed With SEC on January 27, 2014)

INDEMNITY AGREEMENT [For Officers and Directors Not Affiliated withFunds] (Filed With SEC on January 27, 2014)

AMENDMENT NO. 2 TO LOAN AND SECURITY AGREEMENT (Filed With SEC on January 27, 2014)

REVANCE THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on January 27, 2014)

EXECUTIVE EMPLOYMENT AGREEMENT for L. Daniel Browne (Filed With SEC on January 27, 2014)

EXECUTIVE EMPLOYMENT AGREEMENT for Jacob Waugh, M.D. (Filed With SEC on January 27, 2014)

EXECUTIVE EMPLOYMENT AGREEMENT for Lauren Silvernail (Filed With SEC on January 27, 2014)

EXECUTIVE EMPLOYMENT AGREEMENT for Curtis Ruegg, Ph. D. (Filed With SEC on January 27, 2014)

REVANCE THERAPEUTICS, INC. WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on January 27, 2014)

REVANCE THERAPEUTICS, INC. WARRANT TO PURCHASE SHARES OF SERIES PREFERRED STOCK (Filed With SEC on January 27, 2014)

REVANCE THERAPEUTICS, INC. WARRANT TO PURCHASE SERIES D PREFERRED STOCK (Filed With SEC on January 27, 2014)

REVANCE THERAPEUTICS, INC. WARRANT TO PURCHASE CAPITAL STOCK (Filed With SEC on January 27, 2014)

REVANCE THERAPEUTICS, INC. WARRANT TO PURCHASE SHARES OF SERIES PREFERRED STOCK (Filed With SEC on January 27, 2014)

WARRANT AGREEMENT To Purchase Shares of Preferred Stock of REVANCE THERAPEUTICS, INC. Dated as of[ ] (the Effective Date) (Filed With SEC on January 27, 2014)

REVANCE THERAPEUTICS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (Filed With SEC on December 31, 2013)

AMENDMENT NO. 1 TO AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (Filed With SEC on December 31, 2013)

REVANCE THERAPEUTICS, INC. 2002EQUITY INCENTIVE PLAN ADOPTED:OCTOBER 30, 2002 APPROVED BY STOCKHOLDERS:OCTOBER 30, 2002 AMENDED AND RESTATED:FEBRUARY 28, 2003 APPROVED BY... (Filed With SEC on December 31, 2013)

REVANCE THERAPEUTICS, INC. STOCK OPTION GRANT NOTICE (2002 EQUITY INCENTIVE PLAN) (Filed With SEC on December 31, 2013)

REVANCE THERAPEUTICS, INC. AMENDED AND RESTATED 2012 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:DECEMBER 12, 2012 APPROVED BY THESTOCKHOLDERS: DECEMBER 13, 2012... (Filed With SEC on December 31, 2013)

REVANCE THERAPEUTICS, INC. STOCK OPTION GRANT NOTICE AMENDED AND RESTATED 2012 EQUITY INCENTIVE PLAN (Filed With SEC on December 31, 2013)

INDEMNITY AGREEMENT (Filed With SEC on December 31, 2013)

Category

Industry

Companies

Contracts

Revance Therapeutics, Inc. Contracts & Agreements